

MONICA COLQUE-BAYONA¹ , DANIEL LAORDEN² , DAVID ROMERO²,
SANTIAGO QUIRCE^{1,3,4} , JAVIER DOMÍNGUEZ-ORTEGA^{1,3,4} 

Anti-IL5/5R in the treatment of chronic eosinophilic pneumonia and severe asthma

¹Department of Allergy, La Paz University Hospital, Madrid, Spain

²Department of Pulmonology, La Paz University Hospital, Madrid, Spain

³La Paz Institute for Health Research (IdiPAZ), Madrid, Spain

⁴CIBER of Respiratory Diseases (CIBERES), Madrid, Spain

KEY WORDS

Chronic eosinophilic pneumonia; severe asthma; mepolizumab; reslizumab; benralizumab.

Corresponding author

Monica Colque-Bayona

Department of Allergy

La Paz University Hospital

Paseo de la Castellana 261

Madrid, Spain 28046

ORCID: 0000-0003-1534-5573

E-mail: monica.colque@salud.madrid.org

Doi


10.23822/EurAnnACI.1764-1489.323

To the Editor,

chronic eosinophilic pneumonia (CEP) is a rare disease among the diffuse parenchymal lung diseases characterized by significant eosinophil infiltrations in the pulmonary parenchyma and the alveolar spaces (1). Patients with CEP frequently have history of asthma and atopy, therefore it may occur predominantly in patients who are prone to develop a T-helper-2 response. Currently, its diagnosis is based on the presence of respiratory symptoms for at least two weeks, chest radiologic findings (diffuse pulmonary alveolar consolidation and/or ground glass opacities, especially with peripheral predominance), the presence of eosinophilia at bronchoalveolar lavage (BAL) and/or peripheral blood (a BAL cell count differential > 25% or blood eosinophils > 1,000/ μ L), and the absence of other known causes of eosinophilic lung diseases (2). Although oral corticosteroids (OCS) are the mainstay treatment with usually a good response, relapses frequently occur while decreasing or stopping OCS, thus requiring prolonged treatment with the risk of long-term side effects (1, 2).

In last years, the knowledge of eosinophil biology has led to the development of several biologics targeting eosinophils such as biologics targeting interleukin (IL)-5 (mepolizumab and reslizumab) and IL-5 receptor (benralizumab) (3). These therapies have revolutionized glucocorticoid sparing treatment of eosinophilic respiratory diseases (4). Due that eosinophils play a primary role in the pathophysiologic of CEP and the association with asthma (2), eosinophil-specific biologics may be alternative candidates for the treatment. Recent data in case series (5-7) and case reports (8-10) show their potential benefit effect in this disease. Here, we present an additional case series of patients with diagnosis of CEP and concomitant severe eosinophilic asthma treated successfully with anti-IL-5/5R biologics.

We retrospectively analyzed the clinical records of patients with diagnosis of CEP and severe asthma treated with anti IL5/5R therapy in our department from 2010 to 2023. We evaluated the effect of biologic therapy on the daily dose of OCS, number of annual asthma exacerbations, asthma control assessed by

Figure 1 - Chest computed tomography at the moment of diagnosis of chronic eosinophilic pneumonia.

the Asthma Control Test (ACT) and peripheral blood eosinophil counts at baseline and after one year of treatment.

Six patients were included (five women and one man). The mean age at diagnosis of CEP was 39.6 years (from 21 to 49 years). Five had concomitant diagnosis of severe uncontrolled asthma and allergic rhinoconjunctivitis, and one asthma-chronic obstructive pulmonary disease overlap. Two were former smokers. CEP was diagnosed based on the criteria described before (2) and other causes of eosinophilic lung diseases were excluded. Five patients had compatible findings on the lung computed tomography (CT) (**figure 1**) with marked eosinophilia at BAL in three patients (mean of 38% of eosinophils, range 30–49%) and the other two patients presented peripheral blood eosinophilia (1,730 and 4,400/ μ L). One patient was diagnosed by transbronchial lung biopsy. In this patient we could not collect the CT images nor the laboratory data at the moment of the diagnosis. In addition, all the patients underwent screening tests for eosinophilic granulomatosis with polyangiitis (EGPA) and had negative results for proteinase 3 anti-neutrophil cytoplasmic antibodies (PR-3 ANCA) and myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA). Anti-IL-5/IL5R were principally prescribed because of severe uncontrolled asthma and the prolonged glucocorticoid treatment. Prior the biologic therapy, all patients were treated with at least high-dose inhaled corticosteroids plus long-acting β -agonists with poor control of their asthma (mean of ACT 16.6, range from 16 to 18). Five patients were receiving OCS with a mean daily dose of prednisone of 12 mg/day (from 5–30 mg). One patient presented avascular necrosis of the femoral head and shoulder and developed diabetes related to corticosteroid treatment.

Reslizumab was prescribed in two patients (200 and 337 mg every 4 weeks according to the patient's weight), two received mepo-

lizumab (100 mg every 4 weeks) and two benralizumab (30 mg every 8 weeks). One of them had received omalizumab previously. One patient reported headaches associated to mepolizumab. No other adverse effects of biologics were recorded.

After one year of treatment with anti IL5/IL5R, among the five patients with OCS, three could discontinued the corticosteroid treatment; in one patient the daily dose of prednisone was dropped from 30 to 10 mg, and one continued with the same dose (5 mg/day). All patients had reached asthma control according to the ACT (mean 23.3, range 21 to 25) and we found a decrease in the mean of asthma annual rate of exacerbations (from 2.5 to 0.6). Regarding the blood eosinophils count, we found a decrease from a mean 1,316.6/ μ L (400–3,970/ μ L) to 60/ μ L (0–150/ μ L). No relapses of CEP have been observed since the introduction of anti IL-5/5R. No changes in the spirometry values had been observed. The summary of our findings is shown in **table I**.

Although there is clear evidence of the efficacy and safety of anti-IL-5/IL5R in severe asthma that led their approval for its treatment by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA), there is still scarce data of their efficacy on CEP. In the present study, we found that anti-eosinophil biologics were effective in the treatment of both CEP and severe asthma, especially in terms of reducing or discontinuing the OCS therapy and controlling both diseases decreasing asthma exacerbations and CEP relapses. Recently published case series described similar findings: Delcours *et al.* (5) reported a case of series of 29 patients treated with mepolizumab and benralizumab; after a median duration of 13 months, no CEP relapse was reported, the median annual rate of severe asthma exacerbations decreased from 0.15 to 0, and 72% of the patients were eventually weaned from oral corticosteroids. Moreover, Brenard *et al.* (6) reported a case series of

Table I - Clinical and laboratory outcomes after one year of Anti-IL5/5R treatment.

	All patients (n = 6)	Reslizumab (n = 2)	Mepolizumab (n = 2)	Benralizumab (n = 2)
Blood eosinophil count (cells/ μ L)	1,316.6 (400-3,970)	1,180 (520-1,840)	585 (530-640)	2,185 (400-3,970)
Prior treatment	60 (0-150)	65 (60-70)	105 (150-60)	10 (0-20)
After one year				
ACT (mean, range)	16.6 (16-18)	(16-17)	(16-17)	(16-18)
Prior treatment	23.3 (21-25)	(21-24)	(23-25)	(23-24)
After one year				
Number of annual asthma exacerbations (mean, range)	2.5 (1-5)	(1-3)	(3-5)	(1-2)
Prior treatment	0.6 (0-3)	0	(1-3)	0
After one year				
Patients treated with OCS (n)	5	1	2	2
Prior treatment	2	0	1	1
After one year				
Daily dose of prednisone mg/día (mean, range)	12 (5-30)	5	(5-10)	30
Prior treatment	7.5 (5-10)	0	5	10
After one year				

ACT: Asthma Control Test; FEV₁: forced expiratory volume in 1 second; FVC: forced vital capacity; OCS: oral corticosteroids.

10 patients with CEP treated with mepolizumab, after a median follow-up of 9 months, the treatment was associated with a significant annual rate of relapse (from 0.8 to 0), a lower consumption of corticosteroids (tapered from 5 to 0 mg) and also a remission of lung lesions on follow-up high resolution CT. In conclusion, based on our findings and the previous literature, anti-IL-5/5R can be a safe and effective treatment in steroid-dependent patients with CEP and severe asthma.

Fundings

None.

Contributions

All authors: conceptualization, data curation, formal analysis, methodology, writing - original draft, writing - review & editing.

Conflict of interests

The authors declare that they have no conflict of interests.

References

1. Suzuki Y, Suda T. Eosinophilic pneumonia: A review of the previous literature, causes, diagnosis, and management. *Allergol Int.* 2019;68(4):413-9. doi: 10.1016/j.alit.2019.05.006.
2. Cottin V. Eosinophilic Lung Diseases. *Immunol Allergy Clin North Am.* 2023;43(2):289-322. doi: 10.1016/j.iac.2023.01.002.

3. Pitlick MM, Li JT, Pongdee T. Current and emerging biologic therapies targeting eosinophilic disorders. *World Allergy Organ J.* 2022;15(8):100676. doi: 10.1016/j.waojou.2022.100676.
4. Bernstein JS, Wechsler ME. Eosinophilic respiratory disorders and the impact of biologics. *Curr Opin Pulm Med.* 2023;29(3):202-8. doi: 10.1097/MCP.0000000000000951.
5. Delcros Q, Taillé C, Vallée A, Brun AL, Chenivresse C, Couture P, et al. Targeting IL-5/5R for the treatment of idiopathic chronic eosinophilic pneumonia. *J Allergy Clin Immunol Pract.* 2023;11(4):1317-9. e1. doi: 10.1016/j.jaip.2022.12.022.
6. Brenard E, Pilette C, Dahlqvist C, Colinet B, Schleich F, Roufosse F, et al. Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia. *Lung.* 2020;198(2):355-60. doi: 10.1007/s00408-020-00336-3.
7. Sato H, Miyata Y, Inoue H, Tanaka A, Sagara H. Efficacy of Mepolizumab Extended Interval Dosing for 2 Asthmatic Patients With Chronic Eosinophilic Pneumonia. *J Investig Allergol Clin Immunol.* 2021;31(5):459-60. doi: 10.18176/jiaci.0671.
8. Shimizu Y, Kurosawa M, Sutoh Y, Sutoh E. Long-Term Treatment With Anti-Interleukin 5 Antibodies in a Patient with Chronic Eosinophilic Pneumonia. *J Investig Allergol Clin Immunol.* 2020;30(2):154-5. doi: 10.18176/jiaci.0468.
9. Angeletti G, Mazzolini M, Rocca A. Two years follow-up of relapsing eosinophilic pneumonia with concomitant severe asthma successfully treated with benralizumab: A case report and brief review of the literature. *Respir Med Case Rep.* 2023;41:101795. doi: 10.1016/j.rmcr.2022.101795.
10. Izhakian S, Pertzov B, Rosengarten D, Kramer MR. Successful treatment of acute relapse of chronic eosinophilic pneumonia with benralizumab and without corticosteroids: A case report. *World J Clin Cases.* 2022;10(18):6105-9. doi: 10.12998/wjcc.v10.i18.6105.